IC
CPRX

IEQ Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

IEQ Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,661
Closed -$600K – 1894
2025
Q2 		$600K Buy
27,661
+5,140
+23% +$121K ﹤0.01% 1079
2025
Q1 		$546K Buy
22,521
+7,508
+50% +$169K ﹤0.01% 942
2024
Q4 		$313K Buy
+15,013
New +$323K ﹤0.01% 1007

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

IEQ Capital's CPRX Position: Q3 2025 in Review

IEQ Capital sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 27,661 shares — an estimated $600K sold.

IEQ Capital first reported a position in CPRX in Q4 2024 and held it in 3 quarters. The position peaked at $600K in Q2 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • IEQ Capital reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • IEQ Capital sold 27,661 Catalyst Pharmaceutical shares in Q3 2025, an estimated $600K.
  • IEQ Capital first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 3 quarters.
  • IEQ Capital's Catalyst Pharmaceutical position peaked at $600K in Q2 2025.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on IEQ Capital's 13F filing for Q3 2025, filed 14 Nov 2025.